Clinical Trial Update: A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating safety and effectiveness of saroglitazar 4 mg in patients with NAFLD and comorbidities.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemias
• Metabolic Syndrome
• Non-alcoholic Fatty Liver Disease
• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• Saroglitazar (saroglitazar)

Snippet

Sponsor: Zydus Lifesciences Limited | Conditions: NAFLD, Obesity | Phase 4 | Status: UNKNOWN